Cellular Intelligence licenses Novo’s shelved Parkinson’s cell therapy programme
Novo Nordisk shuttered its cell therapy unit in October 2025, with assets now moving to new hands.
Cytiva Navigating cell therapy WP 4
Non-viral gene therapies emerge as key players amid viral safety bottlenecks
Regeneron cuts White House pricing deal, offers new gene therapy for free
Eli Lilly doubles down on in vivo with $7bn Kelonia buyout
The innovators working to make in vivo cell therapy a reality
Rocket’s gene therapy Kresladi wins FDA approval in rare immune disease
Calls for change as access to cell and gene therapies in the Netherlands falls short
Nonprofit models support strategic boldness to develop gene therapies for rare diseases
